Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
21 results
D3.295 - Comparing Real-World and AI-Enabled Market Research in Caregivers of Individuals with Peanut Allergy
D3.296 - Alpha-gal Syndrome with Concomitant Milk Sensitization in a Patient with Asthma and Allergic Rhinitis: A Case Report
D3.297 - De-labelling peanut allergy in a 19-year-old woman with detectable Ara h 2 sensitization: a real-life, exercise-augmented oral food challenge
D3.298 - The Good, the Bad and the Ugly : Mugwort, Mango, and Pineapple
D3.300 - Wheat tolerance induction protocol
D3.301 - Аллергия на белки коровьего молока у детей: сосредоточено на короткоцепочечных жирных кислотах
D3.302 - Sesame as an under-recognized allergen: storage protein sensitization underlying food-induced anaphylaxis in a young adult
D3.303 - Buckwheat Allergy in Bologna Metropolitan Area: Often Severe, Often Hidden
D3.304 - Real-Life Evaluation of the Egg Ladder in a Tertiary Pediatric Allergy Center in Turkey
D3.305 - Isolated IgE-Mediated Anaphylaxis to Pine Nut in an adult
D3.418 - A Phase 1b Study of Lesigercept, a Long-acting High-affinity IgETrap-Fc Fusion Protein: Safety, Tolerability, PK, and PD in Atopic Healthy and Allergic Subjects
D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset
D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study
D3.421 - Real-world Effectiveness and Safety of Lanadelumab Treatment in Patients With Hereditary Angioedema: The 12-Month Interim Analysis of a Polish, Prospective, Multicenter, Observational Study (CHOPIN)
D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes
D3.423 - Lanadelumab treatment is effective and safe in patients with Factor XII associated cold-induced autoinflammatory syndrome: results from an open-label proof-of-concept study
D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria
D3.426 - Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project
D3.427 - Challenging the paradigm: Use of omalizumab in refractory angioedema in a 2-year-old child
D3.428 - Substratification of Biologic Treatment Using Dupilumab in Eosinophilic COPD
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download